Polymeropoulos Mihael Hristos 4

What Happened

• Mihael Hristos Polymeropoulos, President & CEO, Director and Chairman of Vanda Pharmaceuticals (VNDA), was awarded 525,000 restricted stock units (RSUs) on 2026-02-18. The Form 4 reports the grant as an "A" (award/acquisition) at $0.00 per share (total $0 on the filing). These are time‑based RSUs rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-18; reported on Form 4 filed 2026-02-19 (timely filing).
• Reported price on Form 4: $0.00 per share; total shown on filing: $0.
• Shares granted: 525,000 RSUs (representing underlying common stock).
• Shares owned after transaction: not disclosed in the filing.
• Footnote: RSUs vest in four equal annual installments, with first vesting on March 1, 2027, provided continuous employment. Vested shares will be delivered on the first permissible trading day on or after each vesting date.

Context

• These RSUs are compensation awards that vest over time; they do not reflect an immediate cash purchase or sale. The economic value to the insider will depend on Vanda’s stock price when each tranche vests and any applicable tax withholdings. Awards to executives are common and are intended as long‑term compensation rather than an explicit market signal.